Most Read Articles
24 Jun 2015
Persistent sleepless nights can take their toll on sufferers, and leave some insomniacs gasping for a caffeine hit just to get them through the morning slog.
01 Sep 2013
Centella asiatica methanol extract is a promising agent in skin care, a study shows.
14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.
01 Aug 2012

Proper use of family planning methods is the key to preventing unplanned preg­nancies. Despite the great effort spent in the research and development of contra­ceptive methods resulting in many new advances, none of the current methods is 100% effective. Emergency contraception (EC), also called ‘postcoital contraception’, is a back-up contraception adminis­tered to a woman after unprotected sexual intercourse (UPSI) or contraceptive failure, so as to prevent unplanned pregnancy. This may be indicated when unexpected intercourse has occurred without the use of any contraception, when there is a sus­pected potential failure of one’s regular contraceptive method (eg, condom break­age or slippage, missed dose of hormonal contraceptive, or potential failure of an intrauterine contraceptive device), or after sexual assault.

Limited benefit to extending letrozole therapy in postmenopausal breast cancer patients

Roshini Claire Anthony
16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.

After a median follow-up period of 6.9 years, extended letrozole therapy did not improve disease-free survival (DFS) compared with placebo (292 vs 339 events in the letrozole and placebo arms, respectively; hazard ratio [HR], 0.85, 95 percent confidence interval [CI], 0.73–0.999; p=0.048). The 7-year DFS was 84.7 percent vs 81.3 percent in the letrozole and placebo arms, respectively. [SABCS 2016, abstract S1-05]

Extended letrozole therapy also did not improve overall survival (OS; HR, 1.15, 95 percent CI, 0.99–1.44; p=0.22; 7-year OS was 91.8 percent vs 92.3 percent in the letrozole and placebo arms, respectively).

There was a reduction in the risk of recurrence or contralateral breast cancer as first event (breast cancer-free interval [BCFI] events) in women on extended letrozole compared with placebo (127 vs 179 events; HR, 0.71, 95 percent CI, 0.56–0.89; p=0.003), with a 7-year cumulative incidence of 6.7 percent in the letrozole arm vs 10 percent in the placebo arm. Incidence of distant recurrence was also reduced in women on letrozole (73 vs 102 events; HR, 0.72, 95 percent CI, 0.53–0.97; p=0.03).

Between September 2006 and January 2010, 3,966 postmenopausal women with stage I-IIIA HR-positive breast cancer previously treated with adjuvant hormonal therapy (AI for 5 years or tamoxifen for ≤3 years followed by AI to complete 5 years) were randomized to receive either letrozole (2.5 mg/day) or placebo for 5 years.

Letrozole treatment discontinuation due to adverse events occurred in 9.6 percent of participants, while discontinuation due to withdrawal/refusal and disease progression occurred in 13.8 and 4.1 percent of participants, respectively.

Incidence of osteoporotic fractures was comparable between women on letrozole and placebo (91 vs 78 events; HR, 1.19, 95 percent CI, 0.88–1.60; p=0.27), as was incidence of arterial thrombotic events (71 vs 59 events; HR, 1.21, 95 percent CI, 0.85–1.70; p=0.29).

“Letrozole did not significantly increase risk of osteoporotic fractures but risk of arterial thrombotic events was elevated for letrozole after 2.5 years,” said trial lead investigator Dr Terry Mamounas, medical director of the Comprehensive Breast Program at UF Health Cancer Center in Orlando, Florida, US.

“Our findings suggest that careful assessment of potential risks and benefits is required before recommending extended letrozole therapy in patients with early-stage breast cancer,” said Mamounas. Factors to be considered include patient and tumour characteristics, existing comorbidities, bone mineral density, and AI tolerance in the initial 5 years, he said. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
24 Jun 2015
Persistent sleepless nights can take their toll on sufferers, and leave some insomniacs gasping for a caffeine hit just to get them through the morning slog.
01 Sep 2013
Centella asiatica methanol extract is a promising agent in skin care, a study shows.
14 Jan 2018
Patients with a first episode of Clostridium difficile infection (CDI) are likely to respond to treatment with fidaxomicin with no recurrences, a recent study has shown. On the other hand, those with prior CDI episodes are less likely to respond, especially with >1 prior episode, and more likely to recur, which suggests a greater clinical benefit of fidaxomicin earlier in the course of CDI.
01 Aug 2012

Proper use of family planning methods is the key to preventing unplanned preg­nancies. Despite the great effort spent in the research and development of contra­ceptive methods resulting in many new advances, none of the current methods is 100% effective. Emergency contraception (EC), also called ‘postcoital contraception’, is a back-up contraception adminis­tered to a woman after unprotected sexual intercourse (UPSI) or contraceptive failure, so as to prevent unplanned pregnancy. This may be indicated when unexpected intercourse has occurred without the use of any contraception, when there is a sus­pected potential failure of one’s regular contraceptive method (eg, condom break­age or slippage, missed dose of hormonal contraceptive, or potential failure of an intrauterine contraceptive device), or after sexual assault.